Cargando…

Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

BACKGROUND: The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China and worldwide. METHODS: BsAbs research clinical trials information was retrieved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhonghan, Luo, Fan, Cao, Jiaxin, Lu, Feiteng, Zhang, Yang, Ma, Yuxiang, Zeng, Kangmei, Zhang, Li, Zhao, Hongyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369643/ https://www.ncbi.nlm.nih.gov/pubmed/34399818 http://dx.doi.org/10.1186/s13045-021-01126-x

Ejemplares similares

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2021)

Correction to: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2022)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Current trends and challenges in the downstream purification of bispecific antibodies
por: Chen, Serene W, et al.
Publicado: (2021)

Development of bispecific antibodies in China: overview and prospects
por: Zhang, Jing, et al.
Publicado: (2020)

Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
por: Cho, Jaewon, et al.
Publicado: (2022)

Corrigendum to: Development of bispecific antibodies in China: overview and prospects
por: Zhang, Jing, et al.
Publicado: (2022)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Anticancer drug R&D landscape in China
por: Zhao, Shen, et al.
Publicado: (2020)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Immunotherapeutic progress and application of bispecific antibody in cancer
por: Kang, Jingyue, et al.
Publicado: (2022)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Design and Production of Bispecific Antibodies
por: Wang, Qiong, et al.
Publicado: (2019)

Bispecific Antibodies for Diagnostic Applications
por: Parashar, Archana, et al.
Publicado: (2011)

Bispecific Antibodies and Gene Therapy
por: Nettelbeck, Dirk M.
Publicado: (2011)

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
por: Gammelgaard, Odd L, et al.
Publicado: (2022)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
por: Zhang, Tiancheng, et al.
Publicado: (2023)

The development of bispecific antibodies and their applications in tumor immune escape
por: Zhang, Xiaolong, et al.
Publicado: (2017)

Tethered-variable C(L) bispecific IgG: an antibody platform for rapid bispecific antibody screening
por: Kim, Hok Seon, et al.
Publicado: (2017)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

Production of Native Bispecific Antibodies in Rabbits
por: Wang, Wei, et al.
Publicado: (2010)

Bispecific antibodies: design, therapy, perspectives
por: Sedykh, Sergey E, et al.
Publicado: (2018)

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
por: Husain, Bushra, et al.
Publicado: (2018)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Bispecific Antibodies Progression in Malignant Melanoma
por: Tang, Juan, et al.
Publicado: (2022)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

Structural basis of a novel heterodimeric Fc for bispecific antibody production
por: Wei, Hudie, et al.
Publicado: (2017)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
por: Sun, Rui, et al.
Publicado: (2021)

Enhanced antigen immunogenicity induced by bispecific antibodies
Publicado: (1990)

Nanocell targeting using engineered bispecific antibodies
por: Taylor, Karin, et al.
Publicado: (2014)

Quantification of cell surface proteins with bispecific antibodies
por: Panke, C., et al.
Publicado: (2013)

Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
por: Trivedi, A, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kmftmnrq26lutqug5k0o3so1tq